Ki67 and cyclin A as prognostic factors in early breast cancer.: What are the optimal cut-off values?

被引:64
作者
Ahlin, C. [1 ]
Aaltonen, K.
Amini, R-M
Nevanlinna, H.
Fjallskog, M-L
Blomqvist, C.
机构
[1] Orebro Univ Hosp, Dept Oncol, S-70185 Orebro, Sweden
[2] Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden
[3] Univ Uppsala Hosp, Dept Radiol, Uppsala, Sweden
[4] Univ Uppsala Hosp, Dept Clin Immunol, Uppsala, Sweden
[5] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland
[6] Univ Helsinki, Cent Hosp, Dept Obstet & Gynaecol, Helsinki, Finland
[7] Univ Uppsala Hosp, Dept Genet & Pathol, Uppsala, Sweden
关键词
breast cancer; cut-off value; cyclin A; Ki67; tissue microarray;
D O I
10.1111/j.1365-2559.2007.02798.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To find the optimal cut-off values for cyclin A and Ki67 in early breast cancer tumours and to evaluate their prognostic values. Methods and results: Tissue microarray (TMA) slides were constructed from 570 T1-4 N0-1 M0 breast cancer tumours. The TMA slides were stained for cyclin A and Ki67 using immunohistochemistry with commercial antibodies. To investigate the optimal cut-off values for cyclin A, Ki67 average and maximum values the material was split into two parts at cut-offs defined by dividing it into deciles. For each cut-off value the relative risk (RR) for metastasis-free survival (MFS) and overall survival (OS) was calculated comparing patients with high versus low cyclin A or Ki67 expression. When using a cut-off value around the seventh decile, cyclin A and Ki67 score correlated with the highest RR ratio for MFS in the chemotherapy-naive subgroup. Among patients having received adjuvant chemotherapy, no statistically significant differences in MFS or OS were found. Conclusions: The optimal cut-off value for cyclin A average is 8% and for cyclin A maximum value 11%; for Ki67 the corresponding values are 15% and 22%. Additional studies are needed to verify these results.
引用
收藏
页码:491 / 498
页数:8
相关论文
共 34 条
[31]   Revision of the American Joint Committee on Cancer staging system for breast cancer [J].
Singletary, SE ;
Allred, C ;
Ashley, P ;
Bassett, LW ;
Berry, D ;
Bland, KI ;
Borgen, PI ;
Clark, CG ;
Edge, SB ;
Hayes, DF ;
Hughes, LL ;
Hutter, RVP ;
Morrow, M ;
Page, DL ;
Recht, A ;
Theriault, RL ;
Thor, A ;
Weaver, DL ;
Wieand, HS ;
Greene, FL .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3628-3636
[32]  
Sjöström J, 2002, ACTA ONCOL, V41, P334
[33]   Breast cancer patients with p53 pro72 homozygous genotype have a poorer survival [J].
Tommiska, J ;
Eerola, H ;
Heinonen, M ;
Salonen, L ;
Kaare, M ;
Tallila, J ;
Ristimäki, A ;
von Smitten, K ;
Aittomäki, K ;
Heikkilä, P ;
Blomqvist, C ;
Nevanlinna, H .
CLINICAL CANCER RESEARCH, 2005, 11 (14) :5098-5103
[34]   SUPPRESSION OF ENDOGENOUS AVIDIN-BINDING ACTIVITY IN TISSUES AND ITS RELEVANCE TO BIOTIN-AVIDIN DETECTION SYSTEMS [J].
WOOD, GS ;
WARNKE, R .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1981, 29 (10) :1196-1204